These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6482651)

  • 21. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone.
    Charney DS; Heninger GR; Kleber HD
    Am J Psychiatry; 1986 Jul; 143(7):831-7. PubMed ID: 3717421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naltrexone-assisted rapid methadone discontinuation: a pilot study.
    Camarasa X; Khazaal Y; Besson J; Zullino DF
    Eur Addict Res; 2007; 13(1):20-4. PubMed ID: 17172775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dorsal noradrenergic bundle lesions fail to alter opiate withdrawal or suppression of opiate withdrawal by clonidine.
    Britton KT; Svensson T; Schwartz J; Bloom FE; Koob GF
    Life Sci; 1984 Jan; 34(2):133-9. PubMed ID: 6537983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
    Stine SM; Grillon CG; Morgan CA; Kosten TR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2001 Mar; 154(3):274-81. PubMed ID: 11351934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare.
    Rawson RA; Washton AM; Resnick RB; Tennant FS
    Adv Alcohol Subst Abuse; 1984; 3(3):41-9. PubMed ID: 6093484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts.
    Ozaita A; Escribá PV; Ventayol P; Murga C; Mayor F; García-Sevilla JA
    J Neurochem; 1998 Mar; 70(3):1249-57. PubMed ID: 9489748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two new rating scales for opiate withdrawal.
    Handelsman L; Cochrane KJ; Aronson MJ; Ness R; Rubinstein KJ; Kanof PD
    Am J Drug Alcohol Abuse; 1987; 13(3):293-308. PubMed ID: 3687892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal.
    Gold MS; Redmond DE; Kleber HD
    Am J Psychiatry; 1979 Jan; 136(1):100-2. PubMed ID: 364997
    [No Abstract]   [Full Text] [Related]  

  • 29. Indirect serotonergic agonists attenuate neuronal opiate withdrawal.
    Akaoka H; Aston-Jones G
    Neuroscience; 1993 Jun; 54(3):561-5. PubMed ID: 8332249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients.
    Stine SM; Southwick SM; Petrakis IL; Kosten TR; Charney DS; Krystal JH
    Biol Psychiatry; 2002 Apr; 51(8):642-51. PubMed ID: 11955464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial methadone dose in treating opiate addiction.
    Wang RI; Kochar C; Hasegawa AT; Roh BL
    Int J Addict; 1982 Feb; 17(2):357-63. PubMed ID: 7076369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum prolactin and opiate withdrawal.
    Gold MS; Pottash AL; Finn LB; Kleber HD; Extein I
    Psychiatry Res; 1980 May; 2(2):205-10. PubMed ID: 6932063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of naltrexone treatment.
    O'Brien CP; Greenstein R; Woody GE
    NIDA Res Monogr; 1978; (19):315-20. PubMed ID: 218107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pupillometric changes during gradual opiate detoxification correlate with changes in symptoms of opiate withdrawal as measured by the Weak Opiate Withdrawal Scale.
    Rosse RB; Johri S; Goel M; Rahman F; Jawor KA; Deutsch SI
    Clin Neuropharmacol; 1998; 21(5):312-5. PubMed ID: 9789712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
    Stitzer ML; Wright C; Bigelow GE; June HL; Felch LJ
    Drug Alcohol Depend; 1991 Dec; 29(1):39-46. PubMed ID: 1665778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lesions to terminals of noradrenergic locus coeruleus neurones do not inhibit opiate withdrawal behaviour in rats.
    Chieng B; Christie MJ
    Neurosci Lett; 1995 Feb; 186(1):37-40. PubMed ID: 7540267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noradrenergic dysregulation during discontinuation of cocaine use in addicts.
    McDougle CJ; Black JE; Malison RT; Zimmermann RC; Kosten TR; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Sep; 51(9):713-9. PubMed ID: 8080348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discriminative stimulus effects of morphine withdrawal in the dependent rat: suppression by opiate and nonopiate drugs.
    Holtzman SG
    J Pharmacol Exp Ther; 1985 Apr; 233(1):80-6. PubMed ID: 4039002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression.
    Mannelli P; Gottheil E; Peoples JF; Oropeza VC; Van Bockstaele EJ
    Biol Psychiatry; 2004 Aug; 56(4):261-8. PubMed ID: 15312814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence.
    Maldonado R
    Neurosci Biobehav Rev; 1997 Jan; 21(1):91-104. PubMed ID: 8994212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.